Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Algernon's NP-120 reduces fibrosis in in vivo animal model study of IPF

July 3, 2019

GlaxoSmithKline identifies mTOR inhibitors

July 1, 2019

Dupixent obtains U.S. approval for chronic rhinosinusitis with nasal polyposis

June 27, 2019

FDA issues complete response letter for Ryaltris NDA

June 26, 2019

Researchers identify new compounds for respiratory diseases

June 26, 2019

Symdeko obtains FDA approval for cystic fibrosis in children aged 6-11 years

June 25, 2019

Data reported from phase II study of pembrolizumab for recurrent respiratory papillomatosis

June 25, 2019

Phase II proof-of-concept study of REGN-3500 in asthma meets primary endpoint

June 21, 2019

Chinese PLA General Hospital patents compositions comprising bacillus Oscillibacter valericigenes

June 21, 2019

FDA issues complete response letter on use of Bronchitol for adult patients with cystic fibrosis

June 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...